Molecular epidemiology of malaria in Cameroon. XXVI. Twelve-year in vitro and molecular surveillance of pyrimethamine resistance and experimental studies to modulate pyrimethamine resistance

American Journal of Tropical Medicine and Hygiene

Volumn 77, Issue 2, 2007, Pages 221-227

  Tahar, Rachida ^a   Basco, Leonardo K ^a  

^a INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROFOLATE REDUCTASE; PROBENECID; PYRIMETHAMINE; SULFINPYRAZONE; ANTIMALARIAL AGENT; PROTOZOAL DNA;

ADOLESCENT; ADULT; ANTIMALARIAL ACTIVITY; ARTICLE; CAMEROON; DRUG EFFICACY; EXPERIMENTAL STUDY; GENE SEQUENCE; HUMAN; IC 50; IN VITRO STUDY; MALARIA; MOLECULAR EPIDEMIOLOGY; MUTANT; NONHUMAN; PLASMODIUM FALCIPARUM; PREVALENCE; SEQUENCE ANALYSIS; STATISTICAL SIGNIFICANCE; WILD TYPE; ANIMAL; BLOOD; CHEMISTRY; COMPARATIVE STUDY; DNA SEQUENCE; DRUG COMBINATION; DRUG EFFECT; DRUG RESISTANCE; DRUG SENSITIVITY; ENZYMOLOGY; EPIDEMIOLOGY; GENETICS; ISOLATION AND PURIFICATION; MALARIA FALCIPARUM; METABOLISM; MUTATION; PARASITOLOGY; POINT MUTATION; POLYMERASE CHAIN REACTION;

PLASMODIUM FALCIPARUM;

ADOLESCENT; ANIMALS; ANTIMALARIALS; CAMEROON; DNA, PROTOZOAN; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; EPIDEMIOLOGY, MOLECULAR; HUMANS; MALARIA, FALCIPARUM; MUTATION; PARASITIC SENSITIVITY TESTS; PLASMODIUM FALCIPARUM; POINT MUTATION; POLYMERASE CHAIN REACTION; PROBENECID; PYRIMETHAMINE; SEQUENCE ANALYSIS, DNA; SULFINPYRAZONE; TETRAHYDROFOLATE DEHYDROGENASE;

EID: 34848834178     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2007.77.221     Document Type: Article

References (37)

1. Sibley CH, Hyde JE, Sims PF, Plowe CV, Kublin JG, Mberu EK, Cowman AF, Winstanley PA, Watkins WM, Nzila AM, 2001. Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next? Trends Parasitol 17: 582-588.
2. Filler SJ, Kazembe P, Thigpen M, Macheso A, Parise ME, Newman RD, Steketee RW, Hamel M, 2006. Randomized trial of 2-dose versus monthly sulfadoxine-pyrimethamine intermittent preventive treatment for malaria in HIV-positive and HIV-negative pregnant women in Malawi. J Infect Dis 194: 286-293.
3. Macete E, Aide P, Aponte JJ, Sanz S, Mandomando I, Espasa M, Sigauque B, Dobaño C, Mabunda S, DgeDge M, Alonso P, Menendez C, 2006. Intermittent preventive treatment for malaria control administered at the time of routine vaccinations in Mozambican infants: a randomized, placebo-controlled trial. J Infect Dis 194: 276-285.
4. Peters W, 1987. Chemotherapy and Drug Resistance in Malaria. Second edition. London: Academic Press.
5. World Health Organization, 2005. Susceptibility of Plasmodium falciparum to Antimalarial Drugs. Report on Global Monitoring 1996-2004. Geneva: World Health Organization. WHO/HTM/MAL/2005.1103.
6. Foote SJ, Galatas D, Cowman AF, 1990. Amino acids in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance. Proc Natl Acad Sci USA 87: 3014-3017.
7. Peterson DS, Milhous WK, Wellems TE, 1990. Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. Proc Natl Acad Sci USA 87: 3018-3022.
8. Sirawaraporn W, Sathitkul T, Sirawaraporn R, Yuthavong Y, Santi DV, 1997. Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase. Proc Natl Acad Sci USA 94: 1124-1129.
9. Triglia T, Wang P, Sims PFG, Hyde JE, Cowman AF, 1998. Allelic exchange at the endogenous genomic locus in Plasmodium falciparum proves the role of dihydropteroate synthase in sulfadoxine-resistant malaria. EMBO J 17: 3807-3815.
10. Krogstad DJ, Gluzman IY, Kyle DE, Oduola AM, Martin SK, Milhous WK, Schlesinger PH, 1987. Efflux of chloroquine from Plasmodium falciparum: mechanism of chloroquine resistance. Science 238: 1283-1285.
11. Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, Peters GJ, Noordhuis P, Scheper RJ, Borst P, Pinedo HM, Jansen G, 1999. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 59: 2532-2535.
12. Assaraf YG, Rothem L, Hooijberg JH, Stark M, Ifergan I, Kathmann I, Dijkmans BA, Peters GJ, Jansen G, 2003. Loss of multidrug resistance protein 1 expression and folate efflux activity results in a highly concentrative folate transport in human leukemia cells. J Biol Chem 278: 6680-6686.
13. Bakos E, Evers R, Sinko E, Varadi A, Borst P, Sarkadi B, 2000. Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol Pharmacol 57: 760-768.
14. Nzila A, Mberu E, Bray P, Kokwaro G, Winstanley P, Marsh K, Ward S, 2003. Chemosensitization of Plasmodium falciparum by probenecid in vitro. Antimicrob Agents Chemother 47: 2108-2112.
15. Mount DL, Nahlen BL, Patchen LC, Churchill FC, 1989. Adaptations of the Saker-Solomons test: simple, reliable colorimetric field assays for chloroquine and its metabolites in urine. Bull World Health Organ 67: 295-300.
16. Desjardins RE, Canfield CJ, Haynes JD, Chulay JD, 1979. Quantitative assessment of antimalarial activity in vitro by a semi-automated microdilution technique. Antimicrob Agents Chemother 16: 710-718.
17. Basco LK, Ringwald P, 2000. Molecular epidemiology of malaria in Yaounde, Cameroon. VI. Sequence variations in the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene and in vitro resistance to pyrimethamine and cycloguanil. Am J Trop Med Hyg 62: 271-276.
18. Henning L, Felger I, Beck HP, 1999. Rapid DNA extraction for molecular epidemiological studies of malaria. Acta Trop 72: 149-155.
19. Tahar R, Basco LK, 2006. Molecular epidemiology of malaria in Cameroon. XXII. Geographic mapping and distribution of Plasmodium falciparum dihydrofolate reductase (dhfr) mutant alleles. Am J Trop Med Hyg 75: 396-401.
20. Basco LK, 2003. Molecular epidemiology of malaria in Cameroon. XV. Experimental studies on serum substitutes and supplements and alternative culture media for in vitro drug sensitivity assays using fresh isolates. Am J Trop Med Hyg 69: 168-173.
21. Basco LK, 2006. Molecular epidemiology of malaria in Cameroon. XXIII. Experimental studies on serum substitutes and alternative culture media for in vitro drug sensitivity assays using clinical isolates of Plasmodium falciparum. Am J Trop Med Hyg 75: 777-782.
22. Basco LK, Ringwald P, 1998. Molecular epidemiology of malaria in Yaounde, Cameroon. I. Analysis of point mutations in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. Am J Trop Med Hyg 58: 369-373.
23. Basco LK, Ringwald P, 1999. Molecular epidemiology of malaria in Yaounde, Cameroon. IV. Evolution of pyrimethamine resistance between 1994 and 1998. Am J Trop Med Hyg 61: 802-806.
24. Basco LK, 2003. Molecular epidemiology of malaria in Cameroon. XVI. Longitudinal surveillance of in vitro pyrimethamine resistance. Am J Trop Med Hyg 69: 174-178.
25. Basco LK, Foumane Ngane V, Ndounga M, Same-Ekobo A, Youmba JC, Okalla Abodo RT, Soula G, 2006. Molecular epidemiology of malaria in Cameroon. XXI. Baseline therapeutic efficacy of chloroquine, amodiaquine, and sulfadoxine-pyrimethamine monotherapies in children before national drug policy change. Am J Trop Med Hyg 75: 388-395.
26. Basco LK, Same-Ekobo A, Foumane Ngane V, Ndounga M, Metoh T, Ringwald P, Soula G, 2002. Therapeutic efficacy of sulfadoxine-pyrimethamine, amodiaquine and the sulfadoxine-pyrimethamine-amodiaquine combination against uncomplicated Plasmodium falciparum malaria in young children in Cameroon. Bull World Health Organ 80: 538-545.
27. Nzila A, Ochong E, Nduati E, Gilbert K, Winstanley P, Ward S, Marsh K, 2005. Why has the dihydrofolate reductase 164 mutation not consistently been found in Africa yet? Trans R Soc Trop Med Hyg 99: 341-346.
28. Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, Mukadam RA, Rogerson SJ, Lescano AG, Molyneux ME, Winstanley PA, Chimpeni P, Taylor TE, Plowe CV, 2002. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis 185: 380-388.
29. Roper C, Pearce R, Nair S, Sharp B, Nosten F, Anderson T, 2004. Intercontinental spread of pyrimethamine-resistant malaria. Science 305: 1124.
30. Basco LK, Tahar R, Escalante A, 2004. Molecular epidemiology of malaria in Cameroon. XVIII. Polymorphisms of the Plasmodium falciparum merozoite surface antigen-2 gene in isolates from symptomatic patients. Am J Trop Med Hyg 70: 238-244.
31. McCollum AM, Poe AC, Hamel M, Huber C, Zhou Z, Shi YP, Ouma P, Vulule J, Bloland P, Slutsker L, Barnwell JW, Udhayakumar V, Escalante AA, 2006. Antifolate resistance in Plasmodium falciparum: multiple origins and identification of novel dhfr alleles. J Infect Dis 194: 189-197.
32. Cortese JF, Caraballo A, Contreras CE, Plowe CV, 2002. Origin and dissemination of Plasmodium falciparum drug-resistance mutations in South America. J Infect Dis 186: 999-1006.
33. Nair S, Williams JT, Brockman A, Paiphun L, Mayxay M, Newton PN, Guthmann JP, Smithuis FM, Hien TT, White NJ, Nosten F, Anderson TJ, 2003. A selective sweep driven by pyrimethamine treatment in southeast Asian malaria parasites. Mol Biol Evol 20: 1526-1536.
34. Basco LK, 2004. Molecular epidemiology of malaria in Cameroon. XIX. Quality of antimalarial drugs used for self-medication. Am J Trop Med Hyg 70: 245-250.
35. Sowunmi A, Adedeji AA, Fateye BA, Babalola CP, 2004. Plasmodium falciparum hyperparasitaemia in children. Risk factors, treatment outcomes, and gametocytaemia following treatment. Parasite 11: 317-323.
36. Sowunmi A, Adedeji AA, Fateye BA, Fehintola FA, 2004. Comparative effects of pyrimethamine-sulfadoxine, with and without probenecid, on Plasmodium falciparum gametocytes in children with acute, uncomplicated malaria. Ann Trop Med Parasitol 98: 873-878.
37. Sowunmi A, Fehintola FA, Adedeji AA, Gbotosho GO, Falade CO, Tambo E, Fateye BA, Happi TC, Oduola AMJ, 2004. Open randomized study of pyrimethamine-sulphadoxine vs. pyrimethamine-sulphadoxine plus probenecid for the treatment of uncomplicated Plasmodium falciparum malaria in children. Trop Med Int Health 9: 606-614.